- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Biogen's Qalsody granted MHRA approval to treat rare form of motor neurone disease | ||
| Mo | FDA grants fast track designation to Nektar's rezpegaldesleukin in alopecia areata | ||
| Mo | The power of representation, innovation and trust in rare disease clinical trials | ||
| Fr | Sanofi's Sarclisa approved by EC to treat newly diagnosed multiple myeloma | ||
| Fr | Eli Lilly's Alzheimer's disease drug donanemab recommended by CHMP | ||
| Fr | Patient engagement - a journey of health activation | ||
| Do | Merck unveils $3bn cost-cutting plan to support pipeline and new product launches | ||
| Do | Havas Lynx appoints Talin Apkarian as Havas Lynx Hudson managing director | ||
| Mi | Moderna's LP.8.1-adapted COVID-19 vaccine recommended by CHMP | ||
| Mi | Havas Lynx appoints Ayesha Walawalkar as chief strategy officer | ||
| 29.07. | AstraZeneca's Imfinzi granted FDA priority review to treat early-stage gastric cancer | ||
| 29.07. | Roche shares promising data from Alzheimer's disease development portfolio | ||
| 28.07. | AbbVie's Elahere granted MHRA approval to treat platinum-resistant ovarian cancer | ||
| 28.07. | J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma | ||
| 25.07. | Novartis and Matchpoint enter inflammatory disease partnership worth $1bn | ||
| 25.07. | GSK's Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma | ||
| 25.07. | Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies | ||
| 24.07. | Johnson & Johnson's Darzalex approved by EC as first treatment for high-risk SMM | ||
| 24.07. | LEO's Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema | ||
| 24.07. | Abivax shares positive late-stage results for obefazimod in ulcerative colitis | ||
| 23.07. | AstraZeneca unveils plans to boost US footprint with $50bn investment | ||
| 23.07. | Roche's Itovebi granted EC approval to treat advanced breast cancer patients | ||
| 23.07. | NICE recommends ALK's immunotherapy to target underlying cause of hay fever | ||
| 23.07. | FDA appoints George Tidmarsh as director of CDER | ||
| 22.07. | Biogen to boost US manufacturing footprint with $2bn North Carolina investment |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .